Adjuvant Capital Management, LLC is 10% Owner at AN2 Therapeutics, Inc. (ANTX). They have made 1 open-market trade across 1 company since 2023, most recently 2024-01-16.
CIK 0001935084
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ANTX | 1,995,958 | $6.7M |
Shares reported on the most recent Form 4, priced at the 2024-01-18 close.
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.